Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/0008-5472.CAN-14-0337 http://scihub22266oqcxt.onion/10.1158/0008-5472.CAN-14-0337 C4062095!4062095!24824231     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancer+Res 2014 ; 74 (11): 2907-12 Nephropedia Template TP {{tp|p=24824231|t=2014. Discovery of Mesothelin and Exploiting it as a Target for Immunotherapy |pdf=|usr=}}{{24824231}} gab.com Text Discovery of Mesothelin and Exploiting it as a Target for Immunotherapy JO: Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24824231 #FOAvip We have recently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in patients with extensive treatment refractory mesothelioma. These unprecedented tumor responses have prompted us to review how mesothelin was discovered and the advances that led to these tumor responses. This review is not comprehensive but focuses on major developments over the past 20 years since mesothelin was first identified in our laboratory. Mesothelin is a cell-surface glycoprotein whose expression in normal human tissues is restricted to mesothelial cells. Because it is highly expressed by many solid tumors it is an attractive immunotherapy target. Antibody based therapies currently in clinical trials include an immunotoxin, a chimeric monoclonal antibody and an antibody drug conjugate. In addition, a mesothelin tumor vaccine and a mesothelin-CAR are being evaluated in the clinic. SS1P, an anti-mesothelin immunotoxin was the first mesothelin directed therapy to enter the clinic and its use showed that mesothelin targeted therapy was safe in patients. More importantly our recent work has shown that SS1P in combination with pentostatin and cyclophosphamide can result in durable tumor regression in patients with advanced mesothelioma and opens up the possibility that such an approach can benefit patients with many common cancers. Twit Text FOAVip Discovery of Mesothelin and Exploiting it as a Target for Immunotherapy ????Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=24824231 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=24824231 #FOAvip English Wikipedia <ref>{{Cite pmid|24824231}}</ref> Discovery of Mesothelin and Exploiting it as a Target for Immunotherapy #MMPMID24824231 Pastan I; Hassan R Cancer Res 2014[Jun]; 74 (11): 2907-12 PMID24824231show ga We have recently reported that an immunotoxin targeting mesothelin produced durable major tumor regressions in patients with extensive treatment refractory mesothelioma. These unprecedented tumor responses have prompted us to review how mesothelin was discovered and the advances that led to these tumor responses. This review is not comprehensive but focuses on major developments over the past 20 years since mesothelin was first identified in our laboratory. Mesothelin is a cell-surface glycoprotein whose expression in normal human tissues is restricted to mesothelial cells. Because it is highly expressed by many solid tumors it is an attractive immunotherapy target. Antibody based therapies currently in clinical trials include an immunotoxin, a chimeric monoclonal antibody and an antibody drug conjugate. In addition, a mesothelin tumor vaccine and a mesothelin-CAR are being evaluated in the clinic. SS1P, an anti-mesothelin immunotoxin was the first mesothelin directed therapy to enter the clinic and its use showed that mesothelin targeted therapy was safe in patients. More importantly our recent work has shown that SS1P in combination with pentostatin and cyclophosphamide can result in durable tumor regression in patients with advanced mesothelioma and opens up the possibility that such an approach can benefit patients with many common cancers. äDiscovery of Mesothelin and Exploiting it as a Target for Immunotherap(epmc).pdf DeepDyve Pubget Overpricing